SavedAdd your journal

Journals / Türk Dermatoloji Dergisi / 2018 / Cilt: 12 - Sayı: 4

Effect of Omalizumab Therapy on Coagulation Parameters and Total Immunoglobulin E Levels in Patients with Chronic Idiopathic Urticaria and Bullous Pemphigoid

Kronik İdiyopatik Ürtiker ve Büllöz Pemfigoidli Hastalarda Omalizumab Tedavisinin Koagülasyon Parametrelerine ve Total İmmünoglobulin E Düzeylerine Etkisi

Neslihan AKDOĞAN
Başak YALÇIN
Ayşe ÖKTEM
Yıldız HAYRAN
Ahmet ATILAN
Güneş GÜR AKSOY
Pınar İNCE UYSAL
Pages
159–166
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Total IgE levels were increased after omalizumab usage in all study groups (p=0.003) and elevation of IgE levels was found significant for CIU/CSU but not for BP (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to assess the impact of omalizumab on coagulation biomarkers and immunoglobulin E (IgE) levels in chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) and bullous pemphigoid (BP) patients.Methods: Medical records of 31 CIU/CSU and 16 BP patients were reviewed according to the inclusion and exclusion criteria.
📊
Key Findings & Data:Laboratory parameters for coagulation status and IgE levels at baseline and in the first 12-week period of omalizumab therapy were retrieved and analysed in the light of clinical response to the treatment.Results: At baseline, in CIU/CSU patients, IgE levels were significantly higher in responders [184.5 IU/mL (62-307 IU/mL)] than non-responders [25.6 IU/mL (10.8-30.2 IU/ mL)] (p=0.021).
💡
Conclusion & Impact:Total IgE levels were increased after omalizumab usage in all study groups (p=0.003) and elevation of IgE levels was found significant for CIU/CSU but not for BP (p
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to assess the impact of omalizumab on coagulation biomarkers and immunoglobulin E (IgE) levels in chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) and bullous pemphigoid (BP) patients.Methods: Medical records of 31 CIU/CSU and 16 BP patients were reviewed according to the inclusion and exclusion criteria. Laboratory parameters for coagulation status and IgE levels at baseline and in the first 12-week period of omalizumab therapy were retrieved and analysed in the light of clinical response to the treatment.Results: At baseline, in CIU/CSU patients, IgE levels were significantly higher in responders [184.5 IU/mL (62-307 IU/mL)] than non-responders [25.6 IU/mL (10.8-30.2 IU/ mL)] (p=0.021). During the first 12 weeks of omalizumab therapy, a dramatic decrease in D-dimer levels was observed in serial measurements of CIU/CSU (p=0.001) and also BP patients (p=0.017). Total IgE levels were increased after omalizumab usage in all study groups (p=0.003) and elevation of IgE levels was found significant for CIU/CSU but not for BP (p

Özet

Amaç: Bu çalışmanın amacı kronik idiyopatik ürtiker/kronik spontan ürtiker (KİÜ/KSÜ) ve büllöz pemfigoid (BP) hastalarında omalizumabın koagülasyon biyobelirteçleri ve immünoglobulin E (IgE) seviyeleri üzerine etkisini değerlendirmektir. Yöntemler: Dahil etme ve dışlama kriterlerine uygun olan 31 KİÜ/KSÜ ve 16 BP hastasının tıbbi kayıtları gözden geçirilmiştir. Tedavi başlanmasından hemen önce ve omalizumab tedavisinin ilk 12 haftalık periyoduna ait koagülasyon durumuna ilişkin laboratuvar parametreleri ve IgE seviyelerine ilişkin veriler alınarak tedaviye klinik cevap doğrultusunda analiz edilmiştir. Bulgular: Başlangıçta, KİÜ/KSÜ hastalarında, IgE seviyeleri tedaviye cevap veren hastalarda [184,5 IU/mL (62-307 IU/mL)] cevapsızlardan anlamlı biçimde yüksekti [25,6 IU/mL (10,8-30,2 IU/mL)] (p=0,021). Omalizumab tedavisinin ilk 12 haftası sürecinde KİÜ/KSÜ hastalarında (p=0,001) ve ayrıca BP hastalarında (p=0,017) seri ölçümlerde D-dimer seviyelerinde dramatik düşüş gözlendi. Tüm çalışma grubunda omalizumab kullanımından sonra total IgE seviyelerinde yükselme izlendi (p=0,003) ve IgE yükselmesi KİÜ/KSÜ için anlamlı iken BP için değildi (sırası ile p

🔖

Cite This Article

AKDOĞAN, N., YALÇIN, B., ÖKTEM, A., HAYRAN, Y., ATILAN, A., AKSOY, G. G., UYSAL, P. İ. (2022). Effect of Omalizumab Therapy on Coagulation Parameters and Total Immunoglobulin E Levels in Patients with Chronic Idiopathic Urticaria and Bullous Pemphigoid. Türk Dermatoloji Dergisi, Cilt: 12 - Sayı: 4, 159–166. https://ajindex.com/articles/621569

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Choi G, Schultz MJ, Levi M, et al. The relationship between inflammation and the coagulation system. Swiss Med Wkly 2006;136:139-44. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010;38:S26-34. Asero R, Tedeschi A, Riboldi P, et al. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006;117:1113-7.
  2. Asero R, Cugno M, Tedeschi A. Activation of blood coagulation in plasma from chronic urticaria patients with negative autologous plasma skin test. J Eur Acad Dermatol Venereol 2011;25:201-5.
  3. Asero R, Tedeschi A, Riboldi P, et al. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008;63:176-80.
  4. Takahagi S, Mihara S, Iwamoto K, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy 2010;65:649-56.
  5. Baek YS, Jeon J, Kim JH, et al. Severity of acute and chronic urticaria correlates with D-dimer level, but not C-reactive protein or total IgE. Clin Exp Dermatol 2014;39:795-800.
  6. Marzano AV, Tedeschi A, Fanoni D, et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. The British journal of dermatology 2009;160:266-72.
  7. Marzano AV, Tedeschi A, Spinelli D, et al. Coagulation activation in autoimmune bullous diseases. Clin Exp Immunol 2009;158:31-6.
  8. Cugno M, Tedeschi A, Borghi A, et al. Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk. PloS One 2015;10:e0129456. Razin E, Marx G. Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J Immunol 1984;133:3282-5.
  9. Yang YW, Chen YH, Xirasagar S, et al. Increased risk of stroke in patients with bullous pemphigoid: a population-based follow-up study. Stroke 2011;42:319-23.
  10. Marzano AV, Tedeschi A, Polloni I, et al. Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. Clin Exp Immunol 2013;171:76-81.
  11. Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569-73.
  12. Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010;126:665-6.
  13. Saini S, Rosen KE, Hsieh H